Shortly after the end of the second quarter, on July 14, 2010, Merck completed the acquisition of the Millipore Corporation, a leading U.S.-based life science company with headquarters in Billerica, Massachusetts. The aggregate purchase price, including debt and cash, amounted to EUR 5.2 billion (USD 7.0 billion).
As of the third quarter, Millipore will be combined with most of the Performance & Life Science Chemicals division to form a new division called Merck Millipore. This division will consist of three business units – Bioscience, Lab Solutions and Process Solutions.
Transaction costs of EUR 23.7 million were booked in the first quarter under the segment Corporate and Other and have been reclassified in the second quarter to the new Merck Millipore division. Another EUR 8.5 million transaction costs were booked in the second quarter.
|
Merck Millipore | Key figures |
|
XLS | ||
|
|
|
|
|
|
|
EUR million |
2nd quarter |
Change |
Jan.–June |
Change |
|
Total revenues |
– |
– |
– |
– |
|
Gross margin |
– |
– |
– |
– |
|
Research and development |
– |
– |
– |
– |
|
Operating result |
–32.2 |
– |
–32.2 |
– |
|
Exceptional items |
– |
– |
– |
– |
|
Free cash flow |
–8.6 |
– |
–8.6 |
– |
|
Underlying free cash flow |
–8.6 |
– |
–8.6 |
– |